Citations

Clear

59 citation(s) found for "Leighton, JA".

Most of moderate to severe ulcerative colitis patients in academic clinical practice still do not qualify for randomized controlled trials
Elmasry, Sandra, Pasha, Shabana, Kaur, Manreet , Leighton, Jonathan A. , Gurudu, Suryakanth, Ha, Christina , Elmasry, Sandra , Gurudu, Suryakanth R, Ha, Christina , Pasha, Shabana F.

Mayo Clinic

Crohn’s & Colitis 360 | August 4, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/crocol/otag092 | PMID 42633268 Get It

Abstract Background While biologic and small molecule therapies have expanded treatment options for moderate to severe ulcerative colitis (UC), prior research revealed that only 26% of patients in routine practice would have qualified for pivotal randomized controlled trials (RCTs) due to stringent eligibility criteria. This study aimed to evaluate contemporary clinical trial eligibility for UC patients in a tertiary care setting based on more recently approved therapies. Methods We performed a retrospective cohort study of adult patients with moderate to severe UC (total Mayo score ≥6) seen between January 2022 and February 2023. Inclusion and exclusion criteria from seven phase III RCTs conducted between 2012 and 2022 (eg, VARSITY, UNIFI, OCTAVE, LUCENT) were applied to determine patient eligibility and identify reasons for ineligibility. Results Of 150 patients (mean age 44.9 years; 55.7% male), only 42.7% were eligible for at least one RCT. The most common exclusion factor was current or prior medication use, followed by anemia, dysplasia, and disease extent. Trial eligibility did not significantly differ by age, gender, or disease duration. Conclusions Despite modest improvements since 2012, over half of real-world UC patients remain ineligible for current RCTs. Expanding inclusion criteria, especially regarding prior medication exposure, and adopting more inclusive trial designs may enhance external validity. Addressing disparities in trial access and participation remains essential to ensuring equitable representation and improving clinical applicability of RCT findings.
Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials
Santana, Clodomir, Katayama, Asuka, Ballal, Aditya , Liem, David A., Chen, C , Nuno, Miriam, Ebong, Imo, Zhang, Xiao-Dong, Izu, Leighton, Alagna, Laura , Borlaug, Barry A., Butler, Javed, Chirinos, Julio A. , Chutkow, William A., Desai, Akshay S., Desvigne-Nickens, Patrice, Givertz, Michael M., Khan, Sadiya S., Kitzman, Dalane W., Lewis, Gregory D., Redfield, Margaret M., Shah, Sanjiv J., Sharma, Kavita, Taylor, Jennifer , Tinsley, Emily, Wong, Renee, Shah, Sanjiv J., Sirish, Padmini , Liem, David A. , Bidwell, Julie T. , Nuño, Miriam , Ebong, Imo , Izu, Leighton T. , Alagna, Laura, Pesce, Lorenzo L. , Sisk, Ryan K. , Borlaug, Barry A. , Butler, Javed , Desai, Akshay S , Desvigne‐Nickens, Patrice , Givertz, Michael M. , Khan, Sadiya S. , Kitzman, Dalane W. , Lewis, Gregory D. , Rasmussen‐Torvik, Laura J. , Redfield, Margaret M. , Sharma, Kavita , Taylor, Jennifer L., Shah, Sanjiv J , López, Javier E. , Chiamvimonvat, Nipavan , Cadeiras, Martín

Mayo Clinic

No container title available | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.06.26357251 | PMID 42465912 Get It

Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome comprising multiple pathophysiological phenotypes. HFpEF trials have largely enrolled diverse populations and reported average treatment effects, consistently yielding neutral results that may obscure drug-specific benefits within distinct subgroups. To address this issue, we employ an interaction-based that incorporates treatment-by-variable interactions to uncover drug-specific responses. Methods We leveraged four HFpEF clinical trials (TOPCAT, RELAX, NEAT-HFpEF, INDIE-HFpEF) and developed a framework comprising two complementary approaches. The first employed a prognostic responder model to evaluate whether conventional responder definitions reflect treatment-specific benefit or instead capture favorable clinical trajectories common to both treatment and placebo groups. The second used an interaction-based individual treatment effect (ITE) modeling to identify baseline variables that modify therapy effect, distinguishing drug-specific response from prognostic phenotypes. Results Although the prognostic responder model demonstrated good discrimination, further analisys suggested it primarily captured a prognostic signal associated with favorable clinical trajectories common to both treatment and placebo arms. In contrast, the ITE model identified distinct, drug-specific effect modifiers across trials (cardiorenal-inflammatory for spironolactone (TOPCAT), NO-mediated anti-inflammatory for isosorbide mononitrate (NEAT-HFpEF), afterload-reducing for inorganic nitrite (INDIE-HFpEF), and anti–volume-overload for sildenafil (RELAX). Each ITE model demonstrated significance only within its own trial suggesting drug-specific signal. Conclusions The proposed method identifies mechanism-specific effect modifiers, and uncovers clinically meaningful heterogeneity in treatment response, which is not captured by conventional MCID-based approaches. Although exploratory, these findings support phenotype-guided therapy in HFpEF and argue for phenotype-informed trial design to enhance treatment-effect detection and therapy targeting. Graphical Abstract
24 There’s Something There That Wasn’t There Before': A Case of Refractory Ulcerative Colitis and Abnormal Liver Enzymes
McNally, Bridgette B. , Barnhill, Michele , Leighton, Jonathan A. , Ha, Christina

Mayo Clinic

American Journal of Gastroenterology | December 10, 2025 | Volume: 120 | Issue: 12S | Pages: S7-S7

10.14309/01.ajg.0001172520.82998.0d Get It

Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors
Aghaee, Mahya , Qdaisat, Sadeem, Weidert, Frances, Garcia, Gabriel , Fagman, Lana, Stover, Brian, Moor, Rachel S F, Goldenberg, Eden, Chardon‐Robles, Jonathan, Elliott, Leighton , Foster, Timothy P. , Rahman, Maryam, Ghiaseddin, Ashley , Castillo, Paul , Lee, Ji‐Hyun , Doty, Andria , Milner, Rowan J. , Mitchell, Duane A. , Méndez-Gómez, Héctor , Carrera-Justiz, Sheila , Aghaee, Mahya , Doonan, Bently , Deleyrolle, Loic P. , Ligon, John A , Milner, Rowan J , Moore, Helen , Sayour, Elias J , Zhang, Dingpeng , Moor, Rachel S F, Xie, Chao Lian , Goldenberg, Eden, Roemeling, Christina A. Von , Doonan, Bently P. , Sawyer, W. Gregory , Sahay, Bikash , Seligson, Nathan D. , Silver, Natalie L.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | November 11, 2025 | Volume: 13 | Issue: 11 | Pages: e011817

10.1136/jitc-2025-011817 | PMID 41218853 Get It

Malignant glioma is considered invariably recalcitrant, thus necessitating development of new therapeutic approaches. Spontaneously arising canine glioma exhibits important molecular and pathological similarities to malignant pediatric glioma, making it an invaluable model for testing novel therapies. We evaluated safety and activity of RNA lipid particle aggregates (LPAs) designed to provoke cancer immunogenicity in 10 dogs with histologically confirmed glioma. Vaccine manufacturing was feasible in all subjects and generally well tolerated. Median survival time was 123 and 155 days in dogs receiving three (Group A) or four (Group B) vaccines, respectively; this was increased from historical reporting of subjects receiving palliative care. Responding animals had a robust cytokine response following infusions. In animals receiving non-specific RNA-LPAs, there was localization of messenger RNA (mRNA) payloads to the brain tumor microenvironment and a rapid shift in immunologic gene signatures consistent with a viral response. These data demonstrate the ability to induce rapid viremic response in the tumor microenvironment following a single peripherally administered mRNA vaccine. Since RNA-LPAs are amenable to repeat boosts, these formulations may overcome challenges of tumor immunosuppression and therapeutic access and are currently under evaluation in first-in-human trials ( NCT04573140 , NCT06389591 ).
Musculoskeletal trauma rehabilitation: a global comparison
Bernstein, Brian , Lundy, Douglas W. , Miclau, Theodore , Balogh, Zsolt J. , Kitada, Shimpei , Leighton, Ross , Putzeys, Guy , Padilla-Rojas, Luis G. , Vallejo, Linda, Tamayo-Cosio, Jonathan, Zertuche, Darío Esaú Garín , Herrera, Cristian A. Rojas, Hungria, José Octavio Soarez, Camacho, Jaime A. Leal, Caiero, Marcelo Tadeu , Neyra, Horacio Tabares, Pape, Hans‐Christoph , Miclau, Theodore A, Schipper, Inger Birgitta , Herrera, Cristian A. Rojas, Hungria, José Octávio Soares , Leal, Jaime Andrés , Giordano, Vincenzo

Mayo Clinic

OTA International | October 13, 2025 | Volume: 8 | Issue: 6S | Pages: No page available

10.1097/oi9.0000000000000437 | PMID 41098362 Get It

Abstract Rehabilitation after musculoskeletal trauma is globally acknowledged as essential for restoring function and improving quality of life; however, significant variation exists in rehabilitation frameworks and services worldwide. Although certain principles—such as early intervention, structured care pathways, and multidisciplinary approaches—are universally recognized as important determinants of outcomes in trauma patients, their implementation and effectiveness vary considerably due to differences in health care infrastructure, economic resources, policy frameworks, and cultural contexts. Drawing on comparative analyses of rehabilitation frameworks across regions, including North America, Latin America, Europe, Asia-Pacific, and Africa, this paper identifies structural variations, systemic challenges, and innovations that can inform global rehabilitation efforts. Strategic international collaboration focusing on shared learning, standardized protocols, technology integration, and targeted investments is key to creating equitable and sustainable rehabilitation models, especially in resource-limited settings and aging populations.
Successful Handling of Patient Complaints Requires Effective Training of Specialists: A Description of the CODE Training Model for Patient Complaint Excellence
Eliáš, Richard , Bond, J. , Werneburg, Brooke L., Stevens, Sheila K., Leighton, Jonathan A. , Elias, Richard M , Bond, Jennifer R

Mayo Clinic

Journal of Patient Experience | May 27, 2025 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/23743735251342611 | PMID 40438274 Get It

Patient complaints are valuable sources of information for quality improvement and provide an avenue for patient self-advocacy. This paper outlines the development and implementation of a novel training program, termed CODE (Compassion, Operational Support, De-escalation, Empowerment), for patient experience complaint management staff. The program consists of 2 core tracks: procedural training on operational systems and resources, and interpersonal communication training. A dual-track framework ensures practical knowledge to access resources to assist complainants is paired with communication for empathy and human connection. The CODE program's dual-track structure is a key strength, bridging the gap between operational efficiency and compassionate communication. By emphasizing both procedural knowledge and interpersonal skills, it equips healthcare professionals to manage patient complaints successfully. The CODE program represents a novel approach for healthcare institutions seeking to optimize patient experience and complaint-handling performance.
HOPE Experience Essentials: The Next Generation of Service Standards at Mayo Clinic
Packard, Jennifer, Welch, Thomas, Munson, Karee, Leighton, Jonathan A. , Packard, Jennifer, Eliáš, Richard

Mayo Clinic

Patient Experience Journal | May 1, 2025 | Volume: 12 | Issue: 1 | Pages: 192-197

10.35680/2372-0247.1907 Get It

Engaging employees in providing exemplary patient experience has been challenging for healthcare leaders in recent years given the pressures of the regulatory environment, increases in staff burnout and rising patient expectations. Amid these challenges, addressing patient experience remains a top priority for healthcare organizations. A novel intervention has been applied at Mayo Clinic with the goal of improving both employee engagement and patient experience. Previous efforts to teach service excellence involved customer service trainings, sometimes purchased through outside vendors. This new initiative is based on our organizational culture and values, input from our employees and patients, and considers the changing needs of a contemporary healthcare workforce. It leverages management practices shown to boost an employee's sense of equity, achievement, and camaraderie. It also highlights staff motivation to do their best work by involving them in conversations about the essential ingredients that make up both exceptional employee and patient experiences.
ACG 2024 Presidential Speech
Leighton, Jonathan A.

Mayo Clinic

American Journal of Gastroenterology | January 31, 2025 | Volume: 120 | Issue: 2 | Pages: 265-267

10.14309/ajg.0000000000003254 | PMID 39887122 Get It

Interview: Jonathan A. Leighton
Leighton, Jonathan A.

Mayo Clinic

EMJ Gastroenterology | December 20, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.33590/emjgastroenterol/phoo3308 Get It

S1232 Patterns of Abnormal MUC1 Expression in Patients With Pouchitis
Nakhleh, Raouf E. , Camilleri, Michael , Kurdi, Ahmed T. , Faubion, William A. , Leighton, Jonathan A. , Raffals, Laura E., Francis, Fadi, Hashash, Jana G. , Yan, Irene K. , Patel, Tushar , Raffals, Laura E. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S877-S877

10.14309/01.ajg.0001034296.75121.1b Get It